Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jasbir S. Seehra
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Beta
- 1.02
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 2.87
Financials
Revenue
$0.00-100.0%Net Income
$-28.71MEBITDA
$-28.31MFree Cash Flow
$-20.58MEPS (diluted)
$-1.45Shares Outstanding (diluted)
19.80M+122.9%Operating Expenses
$30.94MCash & Debt
$257.61MRevenue by Segment (annual)
$244.06MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $244.06M | $87.01M | $2.34 |
| 2024 | $3.55M | $-187.35M | $-5.00 |
| 2023 | $151.0K | $-152.99M | $-5.20 |
| 2022 | $0.00 | $-104.68M | $-4.15 |
| 2021 | $20.10M | $-58.74M | $-2.52 |
| 2020 | $0.00 | $-45.36M | $-2.93 |
| 2019 | $10.00M | $-12.34M | $-1.39 |
| 2018 | $10.00M | $-1.33M | $-0.15 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.43
- Implied price
- $30.91
- Return from $11.52
- 21.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $15.37 — today's price is already 25.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -2.0% | -1.7% | 5.1% | 10.5% | 15.1% | 19.0% |
| 3.0% | 3.3% | 10.5% | 16.2% | 20.9% | 25.1% |
| 8.0% | 8.3% | 15.9% | 21.8% | 26.8% | 31.1% |
| 13.0% | 13.3% | 21.2% | 27.5% | 32.7% | 37.2% |
| 18.0% | 18.3% | 26.6% | 33.1% | 38.6% | 43.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
150+0.00%Social Signal Score
Mentions (7)
- Newszacks.com·9d ago·Neutral
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
View source ↗ - Newsglobenewswire.com·9d ago·Neutral
…Receive Additional Development Milestone Payment from Partner Takeda LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million devel…
View source ↗ - Newsglobenewswire.com·10d ago·Neutral
… Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase …
View source ↗ - Newsglobenewswire.com·30d ago·Neutral
…Announces $5 Million Share Repurchase Authorization LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a $5 …
View source ↗ - Newszacks.com·36d ago·Neutral
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report? Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·45d ago·Positive
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
View source ↗ - Newszacks.com·45d ago·Negative
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.96 per share
Typical surprise +16.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-1.45 vs $-1.34miss
- Thu, May 14$-1.21 vs $-0.92miss
- Wed, Mar 4$-0.86 vs $-0.49miss
- Wed, Nov 5$-0.18 vs $-1.11beat
- Wed, Aug 6$-0.76 vs $-1.14beat
- Tue, May 6$3.62 vs $-0.01beat
Estimates and results for KROS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KROS officers and directors.
- Bought
- $9.5m
- Sold
- $16.5m
11 trades
14 trades
- Tanini Annitasold
- Lerner Lorena Raquelsold
- Cho Esthersold
- Newton Charles W.sold
- Bienaime Jean Jacquesbought
- Bienaime Jean Jacquesbought
- Bienaime Jean Jacquesbought
- Newton Charles W.sold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KROS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.